Table 2.
CEA immunostaining and cancer phenotype.
| CEA Immunostaining Result | |||||||
|---|---|---|---|---|---|---|---|
| n | Negative (%) | Weak (%) | Moderate (%) | Strong (%) | p | ||
| Invasive breast carcinoma of no special type | pT1 | 491 | 75.2 | 12.0 | 5.3 | 7.5 | 0.5044 |
| pT2 | 369 | 70.5 | 13.6 | 5.1 | 10.8 | ||
| pT3–4 | 80 | 68.8 | 15.0 | 3.8 | 12.5 | ||
| G1 | 153 | 78.4 | 10.5 | 5.2 | 5.9 | 0.1972 | |
| G2 | 472 | 69.9 | 14.0 | 6.6 | 9.5 | ||
| G3 | 345 | 74.2 | 12.5 | 3.5 | 9.9 | ||
| pN0 | 269 | 71.4 | 18.2 | 5.6 | 4.8 | 0.6430 | |
| pN+ | 171 | 66.7 | 20.5 | 8.2 | 4.7 | ||
| pM0 | 137 | 70.1 | 16.8 | 5.1 | 8.0 | 0.8864 | |
| pM1 | 93 | 66.7 | 17.2 | 7.5 | 8.6 | ||
| HER2 negative | 771 | 74.2 | 11.9 | 5.1 | 8.8 | 0.0158 | |
| HER2 positive | 113 | 62.8 | 23.0 | 3.5 | 10.6 | ||
| ER negative | 184 | 83.7 | 8.7 | 2.2 | 5.4 | 0.0005 | |
| ER positive | 662 | 68.9 | 15.4 | 6.0 | 9.7 | ||
| PR negative | 351 | 74.6 | 12.8 | 4.0 | 8.5 | 0.6741 | |
| PR positive | 527 | 71.5 | 13.7 | 5.5 | 9.3 | ||
| Non-triple negative | 701 | 68.9 | 15.4 | 5.6 | 10.1 | <0.0001 | |
| Triple negative | 123 | 91.1 | 4.1 | 2.4 | 2.4 | ||
| Urothelial bladder carcinoma | pTa G2 low | 143 | 93.0 | 5.6 | 0.0 | 1.4 | <0.0001 |
| pTa G2 high | 116 | 75.0 | 20.7 | 0.9 | 3.4 | ||
| pTa G3 | 116 | 66.4 | 26.7 | 3.4 | 3.4 | ||
| pT2 | 136 | 69.1 | 20.6 | 2.9 | 7.4 | 0.0167 | |
| pT3 | 216 | 69.0 | 16.2 | 10.6 | 4.2 | ||
| pT4 | 97 | 76.3 | 17.5 | 2.1 | 4.1 | ||
| G2 | 22 | 68.2 | 22.7 | 4.5 | 4.5 | 0.9255 * | |
| G3 | 427 | 70.7 | 17.6 | 6.6 | 5.2 | ||
| pN0 | 253 | 72.7 | 17.0 | 5.5 | 4.7 | 0.4985 * | |
| pN+ | 170 | 66.5 | 20.6 | 8.2 | 4.7 | ||
| Adenocarcinoma of the pancreas | pT1 | 14 | 21.4 | 14.3 | 7.1 | 57.1 | 0.4277 |
| pT2 | 70 | 10.0 | 27.1 | 11.4 | 51.4 | ||
| pT3 | 373 | 20.6 | 19.0 | 10.7 | 49.6 | ||
| pT4 | 29 | 17.2 | 27.6 | 17.2 | 37.9 | ||
| G1 | 16 | 18.8 | 18.8 | 12.5 | 50.0 | 0.9969 | |
| G2 | 344 | 18.9 | 19.5 | 11.3 | 50.3 | ||
| G3 | 104 | 19.2 | 22.1 | 9.6 | 49.0 | ||
| pN0 | 106 | 19.8 | 17.9 | 13.2 | 49.1 | 0.7820 | |
| pN+ | 379 | 18.5 | 21.4 | 10.6 | 49.6 | ||
| R0 | 249 | 18.5 | 20.9 | 11.6 | 49.0 | 0.8254 | |
| R1 | 198 | 18.2 | 20.7 | 9.1 | 52.0 | ||
| MMR proficient | 440 | 19.3 | 20.7 | 11.8 | 48.2 | 0.2974 | |
| MMR deficient | 4 | 0.0 | 50.0 | 25.0 | 25.0 | ||
| Adenocarcinoma of the stomach | pT1–2 | 57 | 31.6 | 8.8 | 10.5 | 49.1 | 0.6383 |
| pT3 | 110 | 33.6 | 11.8 | 9.1 | 45.5 | ||
| pT4 | 106 | 24.5 | 16.0 | 13.2 | 46.2 | ||
| pN0 | 68 | 27.9 | 8.8 | 19.1 | 44.1 | 0.1081 | |
| pN+ | 204 | 30.9 | 13.7 | 8.3 | 47.1 | ||
| MMR proficient | 232 | 30.6 | 13.8 | 9.9 | 45.7 | 0.0899 | |
| MMR deficient | 37 | 18.9 | 16.2 | 24.3 | 40.5 | ||
| Endometrioid endometrial carcinoma | pT1 | 115 | 79.1 | 20.0 | 0.0 | 0.9 | 0.3498 |
| pT2 | 24 | 83.3 | 12.5 | 4.2 | 0.0 | ||
| pT3–4 | 35 | 88.6 | 11.4 | 0.0 | 0.0 | ||
| pN0 | 50 | 80.0 | 20.0 | 0.0 | 0.0 | 0.7254 | |
| pN+ | 30 | 76.7 | 23.3 | 0.0 | 0.0 | ||
| Endometrioid carcinoma of the ovary | pT1 | 23 | 82.6 | 17.4 | 0.0 | 0.0 | 0.2037 |
| pT2 | 5 | 60.0 | 20.0 | 0.0 | 20.0 | ||
| pT3 | 6 | 50.0 | 33.3 | 0.0 | 16.7 | ||
| pN0 | 21 | 71.4 | 28.6 | 0.0 | 0.0 | 0.0516 | |
| pN1 | 8 | 62.5 | 12.5 | 0.0 | 25.0 | ||
| Serous carcinoma of the ovary | pT1 | 32 | 100.0 | 0.0 | 0.0 | 0.0 | 0.2000 |
| pT2 | 44 | 95.5 | 4.5 | 0.0 | 0.0 | ||
| pT3 | 255 | 99.2 | 0.8 | 0.0 | 0.0 | ||
| pN0 | 83 | 100.0 | 0.0 | 0.0 | 0.0 | 0.1147 | |
| pN1 | 163 | 98.2 | 1.8 | 0.0 | 0.0 | ||
| Adenocarcinoma of the colon | pT1 | 66 | 3.0 | 0.0 | 3.0 | 93.9 | 0.5369 |
| pT2 | 336 | 1.2 | 2.4 | 2.7 | 93.8 | ||
| pT3 | 936 | 1.3 | 1.7 | 3.4 | 93.6 | ||
| pT4 | 345 | 1.2 | 3.5 | 2.9 | 92.5 | ||
| pN0 | 877 | 1.0 | 1.5 | 3.2 | 94.3 | 0.1474 | |
| pN+ | 790 | 1.6 | 2.9 | 3.0 | 92.4 | ||
| V0 | 1225 | 1.1 | 2.2 | 3.1 | 93.6 | 0.6785 | |
| V1 | 432 | 1.9 | 2.1 | 3.2 | 92.8 | ||
| L0 | 629 | 1.1 | 1.3 | 2.7 | 94.9 | 0.1296 | |
| L1 | 1013 | 1.5 | 2.8 | 3.5 | 92.3 | ||
| Right side | 454 | 2.4 | 3.3 | 4.6 | 89.6 | 0.0024 | |
| Left side | 1237 | 0.8 | 1.8 | 2.6 | 94.8 | ||
| MMR proficient | 1162 | 0.6 | 1.3 | 2.0 | 96.1 | <0.0001 | |
| MMR deficient | 88 | 5.7 | 11.4 | 13.6 | 69.3 | ||
| RAS wildtype | 468 | 0.9 | 2.8 | 3.0 | 93.4 | 0.7409 | |
| RAS mutation | 355 | 1.1 | 2.3 | 2.0 | 94.6 | ||
| BRAF wildtype | 124 | 0.8 | 3.2 | 1.6 | 94.4 | 0.0498 | |
| BRAF V600E mutation | 21 | 0.0 | 9.5 | 14.3 | 76.2 | ||
* only in pT2–4 urothelial bladder carcinomas. Abbreviations: pT, pathological tumor stage; G, Grade; pN, pathological lymph node status; pM, pathological status of distant metastasis; R, resection margin status; V, venous invasion; L, lymphatic invasion; PR, progesterone receptor; ER, estrogen receptor; MMR, mismatch repair.